Sarepta Therapeutics, Inc. (SRPT) insider trading

By person

29 insiders · 167 transactions

13.5×

Douglas S. Ingram holds 13.5 times base salary in stock. $15.82M of shares against $1.17M in salary for 2025.

Salary from the company's own proxy. The shares are what Douglas S. Ingram last reported holding, valued at $17.02, the price Common Stock was last bought or sold at on the open market here, on 12 Mar 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Sandesh Mahatme

EVP, CFO & Cbo

—

$49.36M (8) scheduled

−$49.36M

44,284

0.0419%

$753.71K

+1.7%

David T Howton

EVP, General Counsel

—

$42.42M (14) scheduled

−$42.42M

31,871

0.0302%

$542.44K

+48.6%

Michael Andrew Chambers

Director

$23.27M (14)

—

+$23.27M

311,569

0.2950%

$5.30M

+314.4%

Douglas S Ingram

Chief Executive Officer

$14.02M (12)

—

+$14.02M

929,391

0.8799%

$15.82M

—

Richard Barry

Director

$5.49M (7)

$18.77M (5)

−$13.28M

3,123,542

2.96%

$53.16M

0.0%

Alexander Cumbo

EVP, Chief Commercial Officer

—

$12.25M (8) scheduled

−$12.25M

12,008

0.0114%

$204.38K

−40.8%

Hans Lennart Rudolf Wigzell

Director

—

$11.03M (15) scheduled

−$11.03M

42,098

0.0399%

$716.51K

+643.0%

Ryan Edward Brown

EVP, General Counsel

—

$6.55M (8) scheduled

−$6.55M

17,129

0.0162%

$291.54K

+286.5%

Bilal Arif

Chief Tech Ops Officer

—

$2.18M (8) scheduled

−$2.18M

32,500

0.0308%

$553.15K

+37.5%

Shamim Ruff

SVP, Chief Regulatory Affairs

—

$1.65M (5) scheduled

−$1.65M

31,936

0.0302%

$543.55K

+85.3%

M Kathleen Behrens

Director

$219.95K (1)

$1.75M (2) scheduled

−$1.53M

224,357

0.2124%

$3.82M

+85.2%

Ian Michael Estepan

Chief Operating Officer

—

$1.27M (3)

−$1.27M

177,184

0.1677%

$3.02M

+1,225%

Stephen Mayo

Director

—

$603.00K (3)

−$603.00K

18,640

0.0176%

$317.25K

—

Joseph Bratica

Principal Financial Officer

—

$538.35K (3) scheduled

−$538.35K

8,140

0.0077%

$138.54K

0.0%

Dallan Murray

Chief Customer Officer

—

$508.90K (1) scheduled

−$508.90K

38,202

0.0362%

$650.20K

+74.0%

Edward M. MD Kaye

Director

—

$410.00K (1)

−$410.00K

71,229

0.0674%

$1.21M

−1.9%

Louise Rodino-Klapac

President, R&D and Tech Ops

$299.87K (1)

—

+$299.87K

203,900

0.1930%

$3.47M

+2,430%

Kathryn Jean Boor

Director

—

$298.95K (2)

−$298.95K

25,138

0.0238%

$427.85K

—

Claude Nicaise

Director

—

$248.20K (1) scheduled

−$248.20K

48,407

0.0458%

$823.89K

+4,741%

Michael W Bonney

Director

$173.48K (1)

—

+$173.48K

9,126

0.0086%

$155.32K

—

Michael Severino

Chief Executive Officer

—

756,104

0.7158%

$12.87M

—

Ryan Ho-Yan Wong

Chief Financial Officer

—

121,792

0.1153%

$2.07M

+589.8%

Cristin Rothfuss

EVP, General Counsel

—

115,519

0.1094%

$1.97M

+738.4%

Gilmore Neil O'Neill

EVP, R&D & CMO

—

29,070

0.0275%

$494.77K

—

Deirdre P Connelly

Director

—

22,100

0.0209%

$376.14K

—

William Ciambrone

EVP

—

22,099

0.0209%

$376.12K

+8,432%

Mary Ann Gray

Director

—

12,356

0.0117%

$210.30K

+18,071%

John C Martin

Director

—

7,913

0.0075%

$134.68K

—

Jean-Paul Kress

Director

—

2,000

0.0019%

$34.04K

+100.0%

Sarepta Therapeutics, Inc.

What the insiders did Net buying

By person